Seagen goes to Pfiz­er for $43B; Sanofi buys di­a­betes part­ner Proven­tion; Cri­sis avert­ed in SVB demise; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

M&A Mon­day made a ma­jor come­back this week and quick­ly topped the charts as the most-read sto­ry. Don’t miss all the oth­er re­port­ing from End­points get­ting in­to the weeds of oth­er in­ter­est­ing news.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.